Seckinger J, Tönshoff B, Stremmel W, Zeier M, Schmidt J
Klinik für Innere Medizin I, Sektion Nephrologie, Medizinische Universitätsklinik Heidelberg, Heidelberg, Germany.
Dtsch Med Wochenschr. 2010 Oct;135(40):1973-8. doi: 10.1055/s-0030-1263345. Epub 2010 Oct 4.
Combined liver-kidney transplantations (CLKT) and kidney after liver transplantations (KALT) are established treatments for patients with end-stage hepatic and renal disease and the number of transplantations has continuously increased over the past few years. The most frequent indications for CLKT in adults are polycystic kidney disease with severe liver involvement and liver cirrhosis of different origins with concomitant chronic kidney failure due to chronic glomerulonephritis or diabetic nephropathy. In children, CLKT is most frequently required due to primary oxalosis type I. At present the main indication for KALT still is calcineurin inhibitor-induced chronic nephrotoxicity, emphasizing the need for a nephron-sparing long-term immunosuppression in liver transplant recipients. Compared to KALT, the indications for CLKT are not as well defined and the decision must therefore be made on a case-by-case basis by a multidisciplinary team of experienced clinicians to avoid unnecessary transplantations of both organs in patients with reversible kidney failure, given the scarcity of organs for transplantation worldwide. In hepatorenal syndrome CLKT should only be considered if the GFR is lower than 20 ml/min for more than three months or if the patient has been on renal replacement treatment for more than one month. In CLKT, there appears to be a certain immunological protection for the kidney transplant by the liver transplant.
肝肾联合移植(CLKT)和肝移植后肾移植(KALT)是终末期肝病和肾病患者的既定治疗方法,在过去几年中移植数量持续增加。成人CLKT最常见的适应症是严重肝脏受累的多囊肾病以及不同病因的肝硬化合并慢性肾小球肾炎或糖尿病肾病导致的慢性肾衰竭。在儿童中,CLKT最常见的原因是I型原发性草酸盐血症。目前KALT的主要适应症仍然是钙调神经磷酸酶抑制剂引起的慢性肾毒性,这强调了肝移植受者需要一种保留肾单位的长期免疫抑制。与KALT相比,CLKT的适应症尚未明确界定,因此鉴于全球可供移植的器官稀缺,经验丰富的临床医生多学科团队必须逐案做出决定,以避免可逆性肾衰竭患者不必要的双器官移植。在肝肾综合征中,只有当肾小球滤过率低于20 ml/min超过三个月或患者接受肾脏替代治疗超过一个月时,才应考虑CLKT。在CLKT中,肝移植似乎对肾移植有一定的免疫保护作用。